Trials Sponsors Conditions Drugs Pricing

Conditions

B-cell Lymphoma Non-Hodgkin's Lymphoma

Keywords

diffused large B cell lymphoma, DLBCL, R-Chop, bevacizumabDiffuse large B-cell non-Hodgkin's lymphoma.

Outcome Measures

Primary Outcomes (1)

The primary endpoint of this study is cardiac and bevacizumab-specific toxicity. Toxicities will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events v3.0
1 year

Secondary Outcomes (1)

Response rates, failure free survival, and overall survival will be evaluated and are secondary endpoints
5 years

Study Arms (1)

bevacizumab and Rituximab

EXPERIMENTAL

This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)

Drug: bevacizumab, Rituximab

Interventions

bevacizumab, RituximabDrug

6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.

bevacizumab and Rituximab

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
bevacizumab, Rituximab
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age \> 18 years.
Histological proven diffuse large B cell non-Hodgkin's lymphoma (DLBCL) according to the World Health Organization classification including morphological variants. The B cell nature of the proliferation must be verified by the positivity with an anti-CD20 antibody. All histology will be reveiwed by a central Lymphoma Trials Office pathology panel.

Sponsors & Collaborators

Royal Marsden NHS Foundation Trust
Otherlead
Hoffmann-La Roche
Industrycollaborator

Study Sites (2)

David Cunningham, Royal Marsden NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom

Royal Marsden NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom

MeSH Terms

Conditions

Lymphoma, Non-HodgkinLymphoma, B-Cell

Interventions

BevacizumabRituximab

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized

Study Officials

David Cunningham
Royal Marsden NHS Foundation Trust
PRINCIPAL INVESTIGATOR

Enrollment

7 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

November 10, 2008

First Posted

November 11, 2008

Study Start

May 2008

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

bevacizumab and Rituximab

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

bevacizumab and Rituximab

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations